Inspira Technologies to Host COVID-19 Virtual Conference on October 6

Rhea-AI Summary

Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) announced it will host a TechTalk event titled "Has COVID-19 changed the game?" on October 6, 2021, at 1:00 PM EDT. This online conference will focus on the impacts of COVID-19 on medical practices, technology innovations, and capital markets. Key speakers include Dr. Yigal Kassif discussing new COVID-19 treatment paradigms, Tal Dolev on medical startup technologies, and Miri Segal-Scharia covering capital market effects. The event aims to engage healthcare professionals and investors. For registration, visit: registration link.

Positive

• The TechTalk event aims to engage healthcare professionals and investors, potentially increasing awareness and interest in the company's technologies.
• Speakers include notable professionals in the medical field, which may enhance the credibility of the event.

Negative

• The company's ART device has not yet been tested on humans and lacks FDA approval, posing a significant risk to its market potential.

RA'ANANA, Israel, Sept. 30, 2021 /PRNewswire/ -- Inspira Technologies OXY B.H.N. Ltd. (Nasdaq: IINN) (NASDAQ:IINNW) (the "Company" or "Inspira Technologies"), a specialty medical device company engaged in the research, development, manufacturing, and marketing of proprietary respiratory support technologies, today announced that it will host the TechTalk event "Has COVID-19 changed the game?", an online conference for healthcare professionals and investors.

Inspira Technologies' upcoming TechTalk is scheduled on October 6, 2021, at 1:00 pm EDT. For registration, please use the link https://l-p.site/inspirasignin

The TechTalk will explore how COVID-19 has influenced medical treatment paradigm, how medical startups can leverage their technologies to address COVID-19, and how capital markets have been impacted.

The event speakers include Dr. Yigal Kassif, cardiac surgeon, the Chairman of the Israeli Society for ECMO and Director of ECMO Service at the Sheba Medical Center in Israel, who will present recent developments in COVID-19 treatments and case studies.

Tal Dolev, CISA, CPA, Head of Technology Advisory of BDO Israel, will address the issue of how medical startups are leveraging technologies in response to COVID-19.

Miri Segal-Scharia, Chief Executive Officer of MS-IR LLC, will discuss the impact of the COVID-19 pandemic on the capital markets. 

Joe Hayon, President, Chief Financial Officer and Co-Founder of Inspira Technologies, will present the ART device, Inspira Technologies' novel technology and go-to-market strategy.

Inspira TechTalk' agenda:

 1:00 pm EDT                         Opening words

1:05 pm EDT                         The medical perspective - Has COVID-19 changed the treatment paradigm for patients with respiratory failure? Dr. Yigal Kassif, Cardiac Surgeon & Director of ECMO Service at the Chaim Sheba Medical Center at Tel HaShomer in Ramat Gan, Israel| Inspira Technologies' Scientific Advisory Board member

1:20 pm EDT                         The technology perspective - How medical startups are
leveraging technologies in response to COVID-19?  Tal Dolev, CISA, CPA, Partner, Head of Technology Advisory, BDO Israel

1:40 pm EDT                         The capital markets perspective - How has COVID-19 impacted the capital markets? Miri Segal-Scharia, Founder & CEO of MS-IR LLC, a leading investors relations agency in New-York

2:00 pm EDT                         Early Extracorporeal Respiratory Support – Introduction with
the ART device, Inspira's novel technology Joe Hayon, president, Chief Financial Officer and Co-Founder, Inspira Technologies

2:10 pm EDT                         Q&A

                                            Moderator: Mr. George Giles

For more information regarding these events, please visit Inspira's Investor Relations page here.  

Inspira Technologies OXY B.H.N. Ltd.

Inspira Technologies is an innovative medical device company in the respiratory care industry. Inspira is developing the ART device, a cost effective early extracorporeal respiratory support system with an intent to function as an "Artificial Lung" for deteriorating respiratory patients. The ART device designed to utilize a hemo-protective flow approach aimed to rebalance saturation levels while patients are awake and breathing, potentially minimizing the patient's need for mechanical ventilation. The Company's product has not yet been tested or used in humans and has not been approved by the U.S. Food and Drug Administration (FDA).

For more information, please visit our corporate website: 

https://inspira-technologies.com/

For more details:

Miri Segal, Investor Relations, MS-IR LLC
+917-607-8654
msegal@ms-ir.com

View original content:https://www.prnewswire.com/news-releases/inspira-technologies-to-host-covid-19-virtual-conference-on-october-6-301388692.html

SOURCE Inspira Technologies

FAQ

When is the Inspira Technologies TechTalk event?

The TechTalk event is scheduled for October 6, 2021, at 1:00 PM EDT.

What topics will be discussed at the TechTalk event?

Topics include changes in medical treatment paradigms due to COVID-19, technology use by startups, and impacts on capital markets.

Who are the speakers at the Inspira Technologies TechTalk?

Speakers include Dr. Yigal Kassif, Tal Dolev, Miri Segal-Scharia, and Joe Hayon.

How can I register for the Inspira Technologies TechTalk?

You can register for the TechTalk at the following link: registration link.

What is the ART device developed by Inspira Technologies?

The ART device is an early extracorporeal respiratory support system designed to function as an 'Artificial Lung' for patients with deteriorating respiratory conditions.